Sou Hu Cai Jing·2025-11-25 11:07Core Viewpoint - The Shenzhen-Hong Kong Stock Connect Medical Index (983036) closed at 4375.4 points on November 25, with a 0.52% increase and a trading volume of 8.459 billion HKD, indicating a positive market sentiment in the healthcare sector [1]. Group 1: Index Performance - The index had 40 stocks rising and 16 stocks falling on the day, with Ping An Good Doctor leading the gainers at a 4.27% increase, while Ruimaite led the decliners with a 1.98% drop [1]. - The index's turnover rate was 0.84%, reflecting moderate trading activity [1]. Group 2: Component Stocks Details - The top ten component stocks of the index include: - Mindray Medical (14.56% weight, 193.88 HKD, 0.46% increase, market cap 235.068 billion HKD) [1] - Yeye Eye Hospital (11.62% weight, 11.59 HKD, 0.35% increase, market cap 108.081 billion HKD) [1] - Lejin Medical (4.85% weight, 15.80 HKD, 0.45% increase, market cap 29.126 billion HKD) [1] - Aimeike (4.80% weight, 145.54 HKD, -0.31% decrease, market cap 44.039 billion HKD) [1] - Yuyue Medical (4.66% weight, 35.67 HKD, -0.14% decrease, market cap 35.758 billion HKD) [1] - Yingke Medical (3.64% weight, 40.26 HKD, 0.20% increase, market cap 26.362 billion HKD) [1] - Furuishi (3.59% weight, 65.75 HKD, -1.50% decrease, market cap 17.422 billion HKD) [1] - Meinian Health (3.58% weight, 5.42 HKD, 0.74% increase, market cap 21.215 billion HKD) [1] - Sinopharm (3.35% weight, 18.55 HKD, 0.49% increase, market cap 57.888 billion HKD) [1] - Ping An Good Doctor (2.63% weight, 13.33 HKD, 4.27% increase, market cap 28.822 billion HKD) [1]. Group 3: Capital Flow - The net outflow of main funds from the index's component stocks totaled 251 million HKD, while retail investors saw a net inflow of 199 million HKD [1]. - The detailed capital flow indicates that while main funds were withdrawing, retail investors were actively buying into the market [2]. Group 4: Recent Adjustments - In the last 10 days, the index underwent adjustments, adding one new stock, Jianfa Zhixin, which is in the medical biology sector with a market cap of 13.886 billion HKD [3].